Mutation unalysis of the BRCA1 gene in familial and sporudic breast cancer

家族性和散发性乳腺癌BRCA1基因突变分析

基本信息

  • 批准号:
    07457264
  • 负责人:
  • 金额:
    $ 0.83万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 财政年份:
    1995
  • 资助国家:
    日本
  • 起止时间:
    1995 至 1996
  • 项目状态:
    已结题

项目摘要

Predisposing mutations in a BRCA1 gene have been recently identified in 17-9 linked breast and ovarian cancer families. We examined breast cancers consisting of 46 early-onse cases (<35 of age), 12 cases with familial clustering, and 59 bilateral cancers for mutations ir entire coding exons of BRCA1 gene using single strand conformation polymorphism (SSCP) analysis. Four mutaions were detected in this panel of 103 patients ; a flame-shift due to 2-bp deletion at codon 797, a nonsense mutation at codon 1214, two missense mutations, one at codon 271 leading to Val->Met substitution, and the other at codon 1150 leading to Pro->Ser substitution. All of them were germiline mutations ; no somatic mutation were found in these tumors, a finding that support a rather confined role of BRCA1 in breast carcinogenesis. Among the three selection groups, all four mutations were found in patients with bilateral tumors. It therefore appears that bilaterality is a prominent phenotypic halmark of BRCA1 p … More redisposition. These results provide informations for understanding the role of BRCA1 gene mutation in familial forms of breast tumors and will contribute to genetic counseling and presymtomatic diagnosis of members in breast cancer families.To better understand the frequency, distribution and nature of BRCA1 mutations Japanese breast cancer patients, we screened 1,000 unselected primary cancers f mutations in exon 11, which accounts for 61% of the entire BRCA1 coding sequence. Using method based on multiplex single-strand conformational polymorphism (SSCP) analysis multiple restriction fragments generated by restriction-enzyme digestion of amplified DNA,w identified eight mutations including four that we had previously found in a subset of thes cases. All eight were germline mutations ; four of them were non-sense mutations or sma deletions resulting in premature stop codons, and the other four were missense mutation. The Japanese carriers of these mutant BRCA1 alleles had developed breast cancers at age ranging from 45 to 62, five of them bilaterally. Taking into account the effect of various facto such as life-time risk of breast cancer, screening efficiency, and the region examined, w roughly estimate that 2-3 % of breast cancer in Japan is attributable to BRCA1 mutation ar that 1 in 1,500-2,000 Japanese women carry a germline mutation in the BRCA1 gene. Less
最近在17-9个相关的乳腺癌和卵巢癌家族中发现了BRCA1基因的易感突变。我们使用单链构象多态性(SSCP)分析了46例早期乳腺癌(<35岁)、12例家族性聚类和59例双侧乳腺癌(BRCA1基因全编码外显子突变)。在103例患者中检测到4个突变;密码子797缺失2个bp导致的火焰移位,密码子1214无义突变,两个错义突变,一个在密码子271导致Val->Met替换,另一个在密码子1150导致Pro->Ser替换。它们都是种系突变;在这些肿瘤中没有发现体细胞突变,这一发现支持了BRCA1在乳腺癌发生中的作用相当有限。在三个选择组中,所有四种突变都在双侧肿瘤患者中发现。因此,双侧性似乎是BRCA1基因显著的表型特征。这些结果为了解BRCA1基因突变在家族性乳腺肿瘤中的作用提供了信息,并将有助于乳腺癌家族成员的遗传咨询和症状前诊断。为了更好地了解日本乳腺癌患者BRCA1突变的频率、分布和性质,我们筛选了1000例未选择的原发癌症11外显子突变,占整个BRCA1编码序列的61%。使用基于多重单链构象多态性(SSCP)的方法分析由扩增DNA的限制性内切酶酶切产生的多个限制性内切片段,我们确定了8个突变,其中4个是我们之前在这些病例的一个子集中发现的。所有8个都是种系突变;其中4个是非义突变或sma缺失导致过早终止密码子,另外4个是错义突变。携带这些突变BRCA1等位基因的日本人在45岁至62岁之间患上了乳腺癌,其中5人是双侧乳腺癌。考虑到各种因素的影响,如乳腺癌的终生风险、筛查效率和检查的地区,我们大致估计日本2- 3%的乳腺癌可归因于BRCA1突变,即每1,500-2,000名日本女性中就有1名携带BRCA1基因的种系突变。少

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
飯田有俊: "乳癌の発生と遺伝子異常" 外科治療. 74. 39-42 (1996)
Arishitoshi Iida:“乳腺癌的发生和遗传异常”手术治疗。74. 39-42 (1996)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Ito, I., Emi, M.et al.: "Association of Genetic Alterations on Chromosome 17 and Loss of Hormone Receptors in Breast Cancer." Br.J.Cancer.70. 438-441 (1995)
Ito, I.、Emi, M.等人:“乳腺癌中 17 号染色体遗传改变与激素受体缺失的关联”。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Katagiri, T: "Mutations in the BRCA1 gene in Japanese Breast Cancer Patients" Human Mutation. 6(印刷中). (1995)
Katagiri, T:“日本乳腺癌患者的 BRCA1 基因突变”《人类突变》6(出版中)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
飯田 有俊: "遺伝子増幅,再構成(転座),欠失「分子生物学的アプローチによる癌研究プロトコール" 羊上社(横田淳+山田雅編集), 263 (1995)
饭田有俊:“基因扩增、重排(易位)、删除“使用分子生物学方法的癌症研究方案”横神社(由横田淳+山田雅编辑),263(1995)
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Komiya,A.: "Allelic losses at loci on chromosome 10 are associated with motastasis and progression of human prostate cancer." Genes,Chrom.Cancer. 17. 245-253 (1996)
Komiya,A.:“10 号染色体上的等位基因丢失与人类前列腺癌的转移和进展有关。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EMI Mitsuru其他文献

EMI Mitsuru的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EMI Mitsuru', 18)}}的其他基金

Detailed analysis of genome structural alteration on 3p21 and clinical application in environment-related cancers.
3p21基因组结构改变的详细分析及其在环境相关癌症中的临床应用。
  • 批准号:
    16K08982
  • 财政年份:
    2016
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetic diagnogis of breast cancer
乳腺癌的基因诊断
  • 批准号:
    10671573
  • 财政年份:
    1998
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

An optical lipid sensor for the detection of ovarian cancer biomarkers in blood
用于检测血液中卵巢癌生物标志物的光学脂质传感器
  • 批准号:
    24K17704
  • 财政年份:
    2024
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring immune checkpoint pathways as novel therapeutic targets in ovarian cancer
探索免疫检查点通路作为卵巢癌的新治疗靶点
  • 批准号:
    22KK0268
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Exploring ATR and PARP Inhibitors for Ovarian Cancer Management: An Innovative Approach
探索 ATR 和 PARP 抑制剂用于卵巢癌治疗:一种创新方法
  • 批准号:
    494635
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Operating Grants
Decoding the impact of single cell mutational processes in triple negative breast cancer and high grade serous ovarian cancer
解读单细胞突变过程对三阴性乳腺癌和高级别浆液性卵巢癌的影响
  • 批准号:
    477662
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Operating Grants
Combination of plasma gelsolin with radiological imaging for prognostication of ovarian cancer
血浆凝溶胶蛋白与放射成像相结合用于卵巢癌的预后
  • 批准号:
    495885
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Miscellaneous Programs
Lipid molecules regulate the prolifetation of ovarian cancer via LSR
脂质分子通过LSR调节卵巢癌的增殖
  • 批准号:
    23K19506
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Engineering T cells to overcome inhibitory receptor signals that limit the efficacy of adoptive cell therapy against ovarian cancer
改造 T 细胞以克服抑制性受体信号,这些信号限制了过继性细胞疗法对卵巢癌的疗效
  • 批准号:
    10526155
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer
卵巢癌中的歧视、生态失调和种族差异的经历
  • 批准号:
    10371537
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer
衰老相关分泌表型的信号基础及其在上皮性卵巢癌中的意义
  • 批准号:
    10731600
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
Role of miR-195 in Chemo-Resistant Ovarian Cancer
miR-195 在化疗耐药性卵巢癌中的作用
  • 批准号:
    10640540
  • 财政年份:
    2023
  • 资助金额:
    $ 0.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了